Evidence map›Paper›PMID 37816955›Full record

ArticleLeukemia2023

Evaluation of complete response to azacitidine according to the revised International Working Group 2023 response criteria for higher risk MDS. Does it make a difference in patients' outcome?

Anthi Bouchla, Sotirios G Papageorgiou, Argyris Symeonidis, Ioanna Sakellari, Panagiotis Zikos, Thomas P Thomopoulos, Eleftheria Hatzimichael, Athanasios Galanopoulos, Nora-Athina Vyniou, Ioannis Kotsianidis and 1 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Anthi BouchlaSecond Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Sotirios G PapageorgiouSecond Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Argyris SymeonidisDepartment of Internal Medicine, University Hospital of Patras, Rio, Greece.
Ioanna SakellariDepartment of Hematology and Stem cell Transplantation, Georgios Papanicolaou General Hospital, Thessaloniki, Greece.
Panagiotis ZikosDepartment of Hematology, Aghios Andreas General Hospital, Patras, Greece.
Thomas P ThomopoulosSecond Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
Eleftheria HatzimichaelDepartment of Hematology, University Hospital of Ioannina, Ioannina, Greece.ORCID http://orcid.org/0000-0002-4408-5646
Athanasios GalanopoulosDepartment of Hematology, Laikon General Hospital, Athina, Greece.
Nora-Athina VyniouDepartment of Hematology, Laikon General Hospital, Athina, Greece.
Ioannis KotsianidisDepartment of Hematology, Democritus University of Thrace Medical School, Alexandroupolis, Greece.
Vasiliki PappaSecond Propaedeutic Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece. vas_pappa@yahoo.com.ORCID http://orcid.org/0000-0003-0421-9424

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Leukemia, Myeloid, AcuteMyelodysplastic SyndromesAntimetabolites, AntineoplasticAzacitidineHumansRemission InductionTreatment OutcomeAntimetabolites, AntineoplasticAzacitidine

Identifiers

PMID37816955
PMCPMC10681887

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.